Wysdom Radio™

Wysdom

We deliver short, focused episodes on the main concepts and procedures you actually need to know. It’s the perfect clinical companion for your drive to work or your daily workout. Come learn IR on the go! Check us out at https://www.medicalwysdom.ai/

  1. 2d ago

    Seal the Tract: Microfibrillar Collagen After Liver Biopsy

    This episode breaks down the first large study of microfibrillar collagen tract embolization (MCTE) in percutaneous liver biopsy (Arasteh et al., JVIR 2026), a single-center review of routine Avitene tract embolization after ultrasound-guided, nontargeted native and transplant liver biopsy. Following, there is an expert commentary by Dr. Ken Zurcher, the study's senior author and an interventional radiologist with Vascular & Interventional Partners at Banner University Medical Center Phoenix. The Premise: Bleeding remains the most important complication of percutaneous liver biopsy, with major bleeding reported in 0.4–1.4% of cases. Gelatin sponge tract embolization lowers that risk, but evidence for microfibrillar collagen (Avitene) in routine liver biopsy was limited to one small transhepatic access series.The Study: A retrospective cohort at Banner University Medical Center Phoenix (August 2022 to July 2025) included 695 consecutive nontargeted native (73.7%) or transplant (26.3%) liver biopsies, all with a 17-gauge/18-gauge coaxial system and routine MCTE. Targeted lesion biopsies were excluded.The Technique: 0.5 g of microfibrillar collagen is mixed with 3 mL of saline into a paste, loaded into a 1-mL Medallion syringe, and injected through the 17-gauge introducer under ultrasound while the needle is withdrawn, stopping short of the liver capsule to limit pain.Outcomes: Major bleeding occurred in 1 of 695 biopsies (0.14%), and minor bleeding in 1 of 695 (0.14%). The mean number of passes was 2.41. Seventeen patients (2.4%) were readmitted within 30 days, none for biopsy-related events, and 31 (4.5%) returned to the ED with biopsy-attributed symptoms such as pain.Caveats: The study was retrospective and single-center, with no contemporaneous control group, so comparisons are to historical benchmarks. Hemoglobin and imaging were obtained only when symptoms developed, so minor bleeds may be undercounted, and microfibrillar collagen costs more than gelatin sponge.Expert Take: Dr. Zurcher explains why targeted biopsies were excluded to keep the data clean and shares his technique: inject until you see the Avitene on ultrasound, retract in a smooth motion while continuously injecting, and make a definite point of stopping before the capsule. He also covers future comparisons against gelatin sponge, the cost trade-off, and upcoming work using Avitene to close kidney biopsy tracts and transhepatic and transsplenic portal access sheaths.Tune in to learn how routine microfibrillar collagen tract embolization can make liver biopsy safer. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Arasteh A, Kim A, Sprout G, et al. Microfibrillar collagen tract embolization in percutaneous liver biopsy: a single-center experience. J Vasc Interv Radiol. 2026;37(11):109045. doi:10.1016/j.jvir.2026.109045

    Seal the Tract: Microfibrillar Collagen After Liver Biopsy
  2. Nov 11

    Doubling Survival in Intermediate-Stage HCC: Y90 vs DEB-TACE (TRACE)

    This episode breaks down the TRACE phase II randomized trial (Dhondt et al., Radiology 2022) comparing glass yttrium-90 radioembolization with doxorubicin drug-eluting bead chemoembolization (DEB-TACE) for unresectable hepatocellular carcinoma. Following, there is an expert commentary by Dr. Evan Lehrman. . The Premise: TACE is the recommended treatment for intermediate-stage (BCLC B) HCC, and uncontrolled studies suggested Y90 radioembolization could be a safe and effective alternative. TRACE put the two head to head.The Study: A single-center trial at Ghent University Hospital enrolled patients with intermediate-stage HCC, extended to ECOG performance status 1 and to early-stage HCC not eligible for surgery or thermal ablation. At the interim analysis, 72 patients had been randomized: 38 to glass Y90 and 34 to DEB-TACE.Efficacy: Median time to progression was 17.1 vs 9.5 months (HR 0.36), and median overall survival was 30.2 vs 15.6 months (HR 0.48), both favoring Y90. The interim result met the prespecified criteria, and the trial was stopped early for efficacy.Safety: Grade 3 or higher serious adverse events were 39% vs 53%, and 30-day mortality was 0% vs 8.3%. Neither difference was statistically significant.Caveats: The trial was small, single-center and stopped early, and Y90 dosing used standard package-insert dosimetry rather than today's personalized dosimetry.Expert Take: Dr. Lehrman places TRACE alongside LEGACY, RASER and DOSISPHERE as one of the trials reshaping locoregional therapy for HCC. He covers why multifocal BCLC B disease is hard to treat, how staged lobar Y90 was used in more than half of the Y90 arm, why personalized dosimetry might make the results even stronger, and the supporting real-world data from the French PROACTIF registry (989 patients at 34 centers).Tune in to learn whether Y90 should displace DEB-TACE for intermediate-stage HCC. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Dhondt E, Lambert B, Hermie L, et al. 90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology. 2022;303(3):699-710. doi:10.1148/radiol.211806

    Doubling Survival in Intermediate-Stage HCC: Y90 vs DEB-TACE (TRACE)
  3. Nov 4

    Communicating After Complications: The Untaught Procedure

    This episode features a recorded lecture by Dr. Gary Ansel on the "last untaught procedure": communicating with patients and families after a procedural complication, introduced by Dr. Rusty Hofmann. It's the kind of firsthand teaching we're proud to bring to Wysdom. The Premise: Every proceduralist remembers their first catastrophic complication. We rehearse wire crossings and balloon inflations, but almost none of us were taught what to say when we walk into the waiting room afterward.Why It Matters: The US sees 70,000 to 90,000 malpractice claims a year, 25,000 to 40,000 of them related to procedures. Most complications don't become lawsuits because of the complication itself. Many begin because patients believe information was withheld.Complication vs. Error: A complication is a known procedural risk that can occur despite excellent care. A medical error is a preventable deviation from acceptable care, and it should be acknowledged honestly. Either way, don't blame the nurses, the industry rep, the equipment or another physician, and don't declare fault or malpractice, because negligence is a legal conclusion that requires a structured review.The Conversation: Explain what happened, the patient's current condition, what is known and unknown, the immediate plan, and when the family will hear from you again. Lead with empathy, and avoid speculation, blame, defensiveness and jargon.A Case: In a PCI perforation that led to tamponade and a trip to the OR, Dr. Ansel led the family conversation himself, then held a same-day team debrief and reviewed the case for system and training improvements.The Curriculum Gap: Communication-and-resolution programs outperform deny-and-defend, with greater family trust, fewer lawsuits and lower liability costs. Yet post-complication disclosure is rarely standardized or assessed in residency, largely absent from fellowship training, and missing from the major meetings. Dr. Ansel's CLEAR framework offers a structured approach.Tune in to learn why the procedure ends when the sheath comes out, but professionalism begins when you walk into the family waiting room.

    Communicating After Complications: The Untaught Procedure
  4. Oct 28

    Early TIPS in Acute Variceal Bleeding

    This Fundamentals episode breaks down the landmark Early TIPS trial (Garcia-Pagán et al., NEJM 2010) on preemptive covered TIPS for high-risk acute esophageal variceal bleeding. Following, there is an expert commentary by Dr. Michael D. Darcy, retired chief of interventional radiology at Mallinckrodt Institute of Radiology, Washington University in St. Louis. The Premise: Standard care (vasoactive drugs, antibiotics, and banding) fails in 10–15% of patients. Rescue TIPS controls bleeding but often arrives too late, when mortality is already high.The Study: Nine European centers randomized 63 high-risk patients (Child-Pugh C 10–13, or Child-Pugh B 7–9 with active bleeding at endoscopy) within 24 hours of admission to early PTFE-covered TIPS (within 72 hours) versus drugs plus banding with rescue TIPS allowed.Efficacy: The primary composite (failure to control bleeding or clinically significant rebleeding at one year) hit 1 of 32 early-TIPS patients versus 14 of 31 on standard care (P=0.001). One-year freedom from that endpoint was 97% versus 50% (NNT 2.1).Survival: Deaths were 4 versus 12. Six-week survival was 97% versus 67% (NNT 3.3); one-year survival was 86% versus 61% (NNT 4.0).Safety & burden: No technical failures. Hepatic encephalopathy at one year was 28% versus 40% (not statistically significant). ICU days were 3.6 versus 8.6.Caveats: Small open-label trial (63 of 359 screened), highly selected population, one-sided sample-size calculation, baseline imbalance in prior encephalopathy, and educational grant support from Gore.Expert Take: Dr. Darcy puts the paper in context for endovascular practice — why hepatology-led dissemination mattered, why encephalopathy still deserves respect, and why current Viatorr controlled-expansion technique often starts at 6 mm rather than the trial’s 8→10 mm step-up.Tune in to learn when early covered TIPS belongs in the pathway for high-risk variceal bleed. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Garcia-Pagán JC, C**a K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362(25):2370-2379.

    Early TIPS in Acute Variceal Bleeding
  5. Oct 21

    Ablate (RFA) and Stabilize (Cement): OsteoCool RFA for Painful Bone Metastases, with Dr. Jason Levy (OPuS One)

    This masterclass episode breaks down OPuS One, the prospective, multinational study of OsteoCool radiofrequency ablation (RFA) plus cement for painful lytic metastases of the spine and pelvis. Following, there is an expert commentary by Dr. Jason R. Levy of Northside Hospital, Atlanta. The Premise: External beam radiation can take 3 to 6 weeks to relieve bone metastasis pain. OPuS One asked whether ablating the tumor and stabilizing the bone could bring relief faster and keep it.The Study: 206 patients were treated at 15 centers, with lytic or mixed lesions in the thoracolumbar spine, periacetabulum, iliac crest or sacrum. Cement followed RFA in 97% of cases, and technical success was 99%.Efficacy: Worst pain, average pain, pain interference and quality of life improved significantly by day 3, and the improvement was sustained through 12 months.Durability: Complete or partial pain response rose from 53% at day 3 to 74% at 12 months (of n=59), and more patients lowered their opioid dose than raised it at every visit.Safety: Device- or procedure-related adverse events occurred in 6 of 206 patients (2.9%), with no fractures at treated sites.Caveats: OPuS One was a single-arm, industry-funded (Medtronic) study with no comparator and heavy dropout, and the effect of RFA can't be separated from the cement.Expert Take: Dr. Levy explains where ablation and cement fit alongside radiation and systemic therapy in palliative oncology, and what endovascular and image-guided specialists can offer patients with painful bone metastases.Tune in to learn how a single minimally invasive procedure can bring pain relief from bone metastases in days rather than weeks. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Levy J, David E, Hopkins T, et al. Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Study. Cardiovasc Intervent Radiol. 2023;46(5):600-609. https://doi.org/10.1007/s00270-023-03417-x

    Ablate (RFA) and Stabilize (Cement): OsteoCool RFA for Painful Bone Metastases, with Dr. Jason Levy (OPuS One)
  6. Oct 14

    EMMY at 10 Years: Two-Thirds Avoid Hysterectomy

    This fundamentals episode breaks down the 10-year results of the EMMY trial, the Dutch randomized comparison of uterine artery embolization (UAE) versus hysterectomy for symptomatic uterine fibroids, and the longest randomized follow-up of the two treatments reported so far. Following, there is an expert commentary by Dr. James Spies, Chair of Radiology at Georgetown University. The Premise: Since 1995, UAE has been described as an alternative to hysterectomy for symptomatic fibroids. EMMY asked whether the benefit holds up a decade later.The Trial: 28 Dutch hospitals randomized 177 premenopausal women with heavy menstrual bleeding from fibroids, all eligible for hysterectomy, 1:1 between 2002 and 2004. 81 underwent UAE and 75 hysterectomy, with a mean follow-up of 133 months.Efficacy: By 10 years, 28 of 81 UAE patients (35%) had a secondary hysterectomy, 5 of them between years 5 and 10. About two-thirds avoided hysterectomy, and the success rate was 69% after an initially successful UAE.Quality of Life: Generic quality of life improved after treatment in both groups and stayed stable at 10 years with no difference between arms. Urinary and bowel function scores fell in both groups, probably from aging, without significant differences between arms.Satisfaction: 78% of UAE patients and 87% of hysterectomy patients were (very) satisfied (P = .77), and 81% versus 84% would recommend their treatment to a friend.The Catch: Secondary hysterectomies kept accruing beyond 5 years, and UAE failure was associated with BMI above 25 (OR 3.29) and smoking (OR 3.24), so long-term follow-up matters when counseling patients.Expert Take: Dr. Spies calls EMMY one of the landmark studies in uterine embolization, but notes issues that may skew long-term results: 17% of patients did not have both uterine arteries embolized and were counted as procedural failures, partly because many sites were performing their first embolizations, and patient management was handled entirely by gynecologists. As the longest follow-up of a randomized trial, and unlikely to be matched in quality, he says it remains the gold standard for long-term outcomes.Tune in to learn why UAE is a well-documented, less invasive alternative to hysterectomy that eligible patients should be counseled on. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. de Bruijn AM, Ankum WM, Reekers JA, et al. Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 10-year outcomes from the randomized EMMY trial. Am J Obstet Gynecol. 2016. https://doi.org/10.1016/j.ajog.2016.06.051

    EMMY at 10 Years: Two-Thirds Avoid Hysterectomy
  7. Oct 7

    Beyond the Drug: What Makes TACE Work?

    This episode breaks down PRECISION V, the 2010 randomized trial that helped make drug-eluting beads a standard option for hepatocellular carcinoma (HCC), and tests its conclusions against later bland-bead and anatomy data. Following, there is an expert commentary by Dr. Premal Trivedi, Chief of Interventional Radiology at the University of Colorado. The Premise: Conventional TACE uses an unstable lipiodol emulsion that leaks doxorubicin into the systemic circulation. Drug-eluting beads promised to hold the drug in the tumor and block flow permanently.Efficacy: In about 200 BCLC A/B patients, six-month objective response was 51.6% with DC Bead versus 43.5% with conventional TACE (p = 0.11), so the trial missed its primary endpoint. A post hoc advanced-disease subgroup favored the beads (52.4% versus 34.7%).Toxicity: Bead patients received more doxorubicin but had far less alopecia (1.1% versus 20.4%), lower peak ALT and preserved LVEF. Post-embolization syndrome was nearly identical.The Catch: The MSKCC Brown trial compared doxorubicin-loaded beads with bland beads and found essentially the same response and survival, which suggests ischemia, not the drug, is doing the work.Caveats: The trial was an industry-sponsored phase II study with six months of follow-up and no survival endpoints. It was underpowered once the control arm outperformed expectations.Expert Take: Dr. Trivedi notes that systemic doxorubicin alone yields only about a 10% response in HCC, and that most of TACE's benefit comes from the depth and completeness of ischemia.Tune in to learn why the embolization, not the chemotherapy, may be doing the heavy lifting in TACE. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52.

    Beyond the Drug: What Makes TACE Work?
  8. Sep 30

    Infra-popliteal Bioresorbable Stents: The NEJM LIFE-BTK Trial

    This episode breaks down LIFE-BTK, the 2024 New England Journal of Medicine randomized trial testing whether a drug-eluting resorbable scaffold beats plain balloon angioplasty for infrapopliteal artery disease in chronic limb-threatening ischemia. The Premise: Below the knee has been a graveyard of failed devices. A scaffold that resists recoil, elutes an antiproliferative drug, then dissolves promises structural support without a permanent metal cage.Efficacy: In 261 CLTI patients randomized 2:1, one-year freedom from the primary composite was 74% with the scaffold versus 44% with angioplasty, though the separation was driven largely by binary restenosis (76% versus 50%).Acute Mechanics: Core-lab technical success was 91% versus 70%, with bailout stenting needed in 6% of angioplasty cases and none in the scaffold arm.The Catch: Every major safety event was in the scaffold arm, including two perioperative deaths and four above-ankle amputations, three in limbs with patent scaffolds. Wound healing was numerically lower (45% versus 56%).Durability: As the scaffold resorbs, the benefit holds. At three years the composite endpoint remained higher for the scaffold, 59.5% versus 44.8%.Caveats: Only about 3% of screened patients enrolled, lesions were short and lightly calcified, vessel prep was mandatory only in the scaffold arm, and DAPT ran 12 months versus 1, all favoring the scaffold.Tune in to learn how the first fully resorbable below-the-knee scaffold stacked up against angioplasty, and where the trial's design should temper how you apply it. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Varcoe RL, DeRubertis BG, Kolluri R, et al. Drug-eluting resorbable scaffold versus angioplasty for infrapopliteal artery disease. N Engl J Med. 2024;390:9-19. https://doi.org/10.1056/NEJMoa2305637

    Infra-popliteal Bioresorbable Stents: The NEJM LIFE-BTK Trial

Ratings & Reviews

5
out of 5
2 Ratings

About

We deliver short, focused episodes on the main concepts and procedures you actually need to know. It’s the perfect clinical companion for your drive to work or your daily workout. Come learn IR on the go! Check us out at https://www.medicalwysdom.ai/

You Might Also Like